摘要
目的:比较阿托伐他汀和辛伐他汀对急性冠状动脉综合征(ACS)患者早期强化调脂、抗炎作用及安全性。方法:将92例ACS患者随机分成阿托伐他汀组(A组,阿托伐他汀40mg,qn)和辛伐他汀组(B组,辛伐他汀40mg,qn),服药前及服药4、8周测定TC、LDL-C、TG、超敏C反应蛋白(hs-CRP)、谷丙转氨酶(ALT)、谷草转氨酶(AST),并随访1年,记录主要心脑血管事件和药物不良反应。结果:①治疗4、8周后2组TC、LDL-C、TG及hs-CRP均明显降低(P<0.05),组间差异无统计学意义(P>0.05);②2组疗效差异无统计学意义(P>0.05);③2组均能有效降低主要心脑血管事件,组间差异无统计学意义(P>0.05);④2者对肝酶的影响和药物相关不良反应发生率低,差异无统计学意义(P>0.05)。结论:阿托伐他汀和辛伐他汀强化治疗均能显著降低ACS患者的TC、LDL-C、TG、以及hs-CRP水平,疗效和不良反应无差异,具有良好的安全性。
Objective： To compare the effects and safety of atorvastatin versus simvastatin in early intensive treatment on lipid-lowering and anti-inflammation in patients with acute coronary syndrome （ACS）. Method： A total of ninety-two patients with ACS was enrolled and randomized into two groups, including the atorvastatin treatment group （n=47, atorvastatin 40 mg qn） and the simvastatin treatment group （ n= 45, simvastatin 40 mg qn）. Efficacy and safety were determined by measuring changes of parameters including total cholesterol（TC）, low density lipoprotein cholesterol（LDL-C）, triglyceride（TG）, high density lipoprotein cholesterol（HDL-C）, high sensitive C-reactive protein （hs-CRP）, alanine aminotransferase （ALT） and aspartate aminotransferase （AST） levels before treatment and at the end of 4 and 8 week after treatment. Main cardiovascular events and drug-adverse reactions were also recorded. Result： （1）TC、LDL-C、TG、and hs-CRP levels were reduced significantly after 4 weeks or 8 weeks in two groups, and presented no difference between two groups. （2）There was no significant difference to therapeutic effect between two groups. （3）The main cardio-cerebral vascular events were decreased in two groups and no difference was found between them. （4）Incidence of adverse reactions as influence on liver enzyme was low and no difference was found between two groups. Conclusion： The efficacy of atorvastatin on serum TC, LDL-C, TG and hs-CRP in patients with ACS are the same as those of simvastatin. No differences of therapeutic effect and adverse effects are found between them, suggesting that intensive dose statins is feasible and safe.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2008年第9期647-650,共4页
Journal of Clinical Cardiology
